Literature DB >> 17970643

Leuprolide acetate: a drug of diverse clinical applications.

Andrea C Wilson1, Sivan Vadakkadath Meethal, Richard L Bowen, Craig S Atwood.   

Abstract

Leuprolide acetate is a synthetic nonapeptide that is a potent gonadotropin-releasing hormone receptor (GnRHR) agonist used for diverse clinical applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques. As its basic mechanism of action, leuprolide acetate suppresses gonadotrope secretion of luteinizing hormone and follicle-stimulating hormone that subsequently suppresses gonadal sex steroid production. In addition, leuprolide acetate is presently being tested for the treatment of Alzheimer's disease, polycystic ovary syndrome, functional bowel disease, short stature, premenstrual syndrome and even as an alternative for contraception. Mounting evidence suggests that GnRH agonist suppression of serum gonadotropins may also be important in many of the clinical applications described above. Moreover, the presence of GnRHR in a multitude of non-reproductive tissues including the recent discovery of GnRHR expression in the hippocampi and cortex of the human brain indicates that GnRH analogs such as leuprolide acetate may also act directly via tissue GnRHRs to modulate (brain) function. Thus, the molecular mechanisms underlying the therapeutic effect of GnRH analogs in the treatment of these diseases may be more complex than originally thought. These observations also suggest that the potential uses of GnRH analogs in the modulation of GnRH signaling and treatment of disease has yet to be fully realized.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970643     DOI: 10.1517/13543784.16.11.1851

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  29 in total

1.  Urinary metabolite markers of precocious puberty.

Authors:  Ying Qi; Pin Li; Yongyu Zhang; Lulu Cui; Zi Guo; Guoxiang Xie; Mingming Su; Xin Li; Xiaojiao Zheng; Yunping Qiu; Yumin Liu; Aihua Zhao; Weiping Jia; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-10-25       Impact factor: 5.911

2.  Sex differences in visuospatial abilities persist during induced hypogonadism.

Authors:  Gioia M Guerrieri; Paul G Wakim; P A Keenan; Linda A Schenkel; Kate Berlin; Carolyn J Gibson; David R Rubinow; Peter J Schmidt
Journal:  Neuropsychologia       Date:  2015-12-21       Impact factor: 3.139

Review 3.  Uterine fibroids and current clinical challenges.

Authors:  Salama S Salama; Gökhan S Kılıç
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-03-01

Review 4.  Peptide-Based Therapeutics for Oncology.

Authors:  Elizaveta Fisher; Kirill Pavlenko; Alexander Vlasov; Galina Ramenskaya
Journal:  Pharmaceut Med       Date:  2019-02

5.  Changes in body composition and mRNA expression of ghrelin and lipoprotein lipase in rats treated with leuprolide acetate, a GnRH agonist.

Authors:  Carlos Olvera-Sandoval; Gabriel Betanzos-Cabrera; Rafael Casillas-Peñuelas; J Luis Quintanar
Journal:  Exp Ther Med       Date:  2017-10-23       Impact factor: 2.447

6.  Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Steven L Highfill; Angela Panoskaltsis-Mortari; Patricia A Taylor; Richard L Boyd; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

7.  Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis.

Authors:  Irene Guzmán-Soto; Eva Salinas; Irma Hernández-Jasso; J Luis Quintanar
Journal:  Neurochem Res       Date:  2012-07-26       Impact factor: 3.996

8.  Formulation of 99mTechnetium-labeled leuprolide loaded liposomes and its biodistribution study in New Zealand white female rabbits for assessment of its uterine targeting efficiency.

Authors:  Arpita Patel; Amit Tyagi; Rakesh Kumar Sharma; Hetal Thakkar
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

9.  Obstructive uropathy secondary to uterine leiomyoma in a chimpanzee (Pan troglodytes).

Authors:  Patrick W Hanley; Kirstin F Barnhart; William C Satterfield; Mark J McArthur; Stephanie J Buchl; Wallace B Baze
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

10.  Administration of luteinizing hormone releasing hormone agonist for synchronization of estrus and generation of pseudopregnancy for embryo transfer in rats.

Authors:  Tiffany M Borjeson; Jassia Pang; James G Fox; Alexis García
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.